Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBITDA Margin for 10 consecutive years, with 145.56% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 21984.0% to 145.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17.83% through Dec 2025, up 7788.0% year-over-year, with the annual reading at 17.83% for FY2025, 7788.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 145.56% at Ultragenyx Pharmaceutical, up from 106.85% in the prior quarter.
  • The five-year high for EBITDA Margin was 145.56% in Q4 2025, with the low at 248.14% in Q3 2022.
  • Average EBITDA Margin over 5 years is 110.82%, with a median of 108.62% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 22511bps in 2021, then tumbled -13812bps in 2022.
  • Over 5 years, EBITDA Margin stood at 122.99% in 2021, then dropped by -15bps to 140.91% in 2022, then surged by 32bps to 95.83% in 2023, then grew by 22bps to 74.28% in 2024, then surged by 296bps to 145.56% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 145.56%, 106.85%, and 64.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.